Morning Brief — Friday, August 14, 2026

Market Overview

The S&P 500 closed at record highs overnight, driven by cooling inflation data (PPI) and a wave of strong earnings reports across healthcare, software, and memory. Risk appetite is firmly “on” — riskiest trades are outperforming, drone stocks are surging on Trump tariff tailwinds, and the WDAY take-private rumor is injecting fresh M&A premium into beaten-up software names. Applied Materials is the lone drag, falling post-earnings as solid results simply weren’t good enough at current valuations — a reminder that “priced for perfection” is a real risk in this market.

Claude’s Call

UP — The combination of S&P 500 record close, broad-based earnings beats across sectors, RDDT’s index inclusion forcing mechanical buying, and a clear risk-on rotation into high-beta names sets up a grind-higher Friday. Tariff-driven drone sector momentum and WDAY M&A chatter add speculative fuel; don’t fight this tape until volume dries up.

Top Movers

ETON (+41.6%) — $57.79 → $68.15 (+17.9% upside) Thesis: This is the real deal — not sector sympathy. ETON delivered a revenue beat of +38% over estimates (+218% EPS surprise), nearly doubled YoY revenue to $37.6M driven by HEMANGEOL relaunch and its rare-disease pediatric portfolio, and raised full-year guidance. At a 6-month high with RSI at a neutral 50 (not yet overbought), the stock actually has room before it gets stretched. Craig-Hallum already had a $62 target pre-earnings; today’s print demands a reset higher. Levels: Exit at Fib 1.272 extension of $68.15. Support at Fib 23.6% retracement of $47.60 — a healthy 17% cushion below current price. SMA-50 at $38.79 is your disaster stop.

OMER (+26.6%) — $17.35 → $19.71 (+13.6% upside) Thesis: YARTEMLEA is the real mover here — Q2 net sales of $28.5M against estimates that implied a ~$12M quarter (a 130% revenue beat), and the drug nearly tripled QoQ from $11.1M to $32.2M gross. This is a genuine commercial launch inflection, not a one-quarter wonder. First positive operating cash flow, debt reduction, and share buybacks signal management confidence. Five-year high breakout on a biotech launch is historically sticky if the drug continues to ramp. Levels: Exit at Fib 1.272 extension of $19.71. Support at Fib 23.6% of $15.30. NOTE: Volume ratio is extremely low (0.12) — this is a thin float move, meaning gaps can fill violently. Size accordingly. Valuation at 239x forward P/E is genuinely expensive vs. peers at 14.6x, but launch-phase biotechs don’t trade on earnings — they trade on script trajectory.

AVAH (+24.8%) — $11.29 → $13.13 (+16.3% upside) Thesis: Aveanna beat earnings by 29% and revenue by 3.6%, raised full-year guidance, and is showing genuine operational improvement — higher reimbursement rates, volume growth, and margin expansion across all three segments. At an RSI of 26 (oversold entering today’s move), this is a classic “bad sentiment + good results = violent re-rating.” Home health is a structural winner as the U.S. ages and payers push patients out of hospitals. This isn’t a meme — it’s a business improvement story. Levels: Exit at Fib 1.272 of $13.13. Nearest support at Fib 23.6% of $10.37, just below the 20d low of $8.95. SMA-50 at $8.89 is your ultimate stop.

HTFL (+23.3%) — $38.24 → $44.96 (+17.6% upside) Thesis: HeartFlow delivered a 48% revenue beat on top of a 12.96% revenue surprise vs. estimates — that’s a double-beat with real margin expansion (83.3% gross margin is best-in-class for medtech SaaS). U.S. revenue up 51% driven by Plaque Analysis, which is still in early adoption. This is an AI-powered cardiology diagnostics platform expanding CCTA penetration — a structural, multi-year TAM expansion story, not a trade. Raised full-year guidance. RSI at 34.5 suggests room before overbought. Levels: Exit at Fib 1.272 of $44.96. Support at Fib 23.6% of $35.19. The 20d low of $24.12 is your stop if thesis breaks.

WDAY (+17.8%) — $206.45 → $232.00 (+12.4% upside) Thesis: Silver Lake take-private rumors are the catalyst, and PE firms don’t leak these casually — this has teeth. Workday has been beaten down hard (6-month low was $112.50), and at a forward P/E of 16x vs. peers at 13.5x (nearly FAIR per our comps), a take-private at even a 30% premium to recent lows implies a >$250 target. Jefferies raised to $205, Ives says no “SaaS Apocalypse.” The stock just reclaimed its 6-month high. This move may have legs beyond today if deal chatter firms up. Levels: Exit at Fib 1.272 extension of $232.00. Support at Fib 23.6% of $184.28 — a clean entry zone if it pulls back. RSI at 37 entering today means there’s technical room to run.

WIX (+16.5%) — $80.06 → $108.43 (+35.4% upside) Thesis: Symphony by Wix AI agent platform launch + Citi price target increase + Q2 beat (revenue +14.9%, EPS +15.3% vs. estimates) = triple catalyst stack. The valuation case is actually compelling: forward P/E of 11.2x vs. peer median of 44.6x makes WIX flagrantly CHEAP on our comps model. This is a profitability-pivoting web platform adding AI capabilities at a discount to every SaaS peer. The RSI of 38.65 says this isn’t overheated. Levels: Exit at 6-month high resistance of $93.89 first; then Fib 1.272 at $108.43 if that breaks. Support at Fib 38.2% of $73.47. Watch the $81.27 Fib 23.6% level — that’s light overhead resistance right above current price.

RDDT (+11.2%) — $175.89 → $184.05 (+4.6% short-term) → $225.42 (+28.2% extended) Thesis: S&P 500 inclusion on August 18 is a mechanical forced-buy event — index funds must accumulate nearly 3x average daily volume in the next few trading sessions. Reddit also has 8 consecutive quarters of 60%+ revenue growth, making this not just an index trade but a fundamentally strong name getting a forced re-rating. The short-term target is $184.05 (Fib 23.6% resistance), but the 1.272 extension at $225.42 is achievable over 1-2 weeks as indexers accumulate. Levels: Near-term resistance at $184.05 (Fib 23.6% from 6mo range) and prior 20d high of $185.84. Support at $172.16 (Fib 38.2%). SMA-50 at $175.08 is right at current price — a close below there is a warning sign.

SNDK (+13.7%) — $1,528.11 → $1,908.39 (+24.9% upside) Thesis: $14 billion buyback announcement, Korean KOSPI returning to bull market territory with SK Hynix and Samsung rallying, and Morgan Stanley checks showing enterprise storage strengthening — this is a multi-vector memory rally with legs. WSB is 80% bullish with 1,521 upvotes. Wall Street is scrambling to reset targets. The stock is below its SMA-50 of $1,654 and well off the 6-month high of $2,335 — there’s real room to recover. This isn’t a pump; it’s a sector re-rating. Levels: First target at SMA-50 of $1,654. Then Fib 38.2% support-turned-resistance at $1,644. Upside target at Fib 23.6% of $1,908. Caution: the 6-month high was $2,335 and the stock is BELOW multiple Fib retracements — it’s recovering, not extending.

NU (+13.4%) — $15.80 → $19.14 (+21.1% upside) Thesis: Nu Holdings crossed $1 billion quarterly net income for the first time (+49% YoY, +17% QoQ), with ROE hitting a record — this is a digital banking platform in hypergrowth mode across Latin America. At $15.80, it’s still below its 6-month high of $17.53. This is a genuine fundamental earnings catalyst, not hype. The combination of expanding customer base, deepening credit income, and first-ever $1B quarterly profit quarter is the kind of milestone that attracts new institutional buyers. Levels: Exit at Fib 1.272 of $19.14. Immediate resistance at Fib 23.6% of $16.13 (just above current price). Support at Fib 38.2% of $15.26 and SMA-50 of $13.48.

UMAC (+20.5%) — $32.81 → $39.49 (+20.3% upside) Thesis: Two catalysts stacking: 687% YoY revenue surge from its own earnings + Trump’s 100% tariff on imported drones creating a moat for domestic manufacturers overnight. This is policy-driven sector rotation with company-specific fundamental support. RSI at 70.8 is the only yellow flag — it’s approaching overbought. Trump tariff pumps historically fade within 48-72 hours unless there’s company-specific follow-through, but UMAC has the earnings to back it up. Levels: Exit at Fib 1.272 of $39.49 (near prior 6-month high of $33.42 is first resistance). Support at Fib 23.6% of $28.15. Warning: RSI at 70.8 means don’t chase — wait for a 1-day pullback to $28-$30 for better entry.

AEHR (+15.8%) — $142.75 → $172.34 (+20.8% upside) Thesis: $22M follow-on AI chip production order from its lead wafer-level customer, record $100.6M backlog, return to profitability, and fiscal 2027 revenue guidance well above Street — this is a picks-and-shovels AI semiconductor play. Wafer-level burn-in (WLBI) demand is structurally rising as AI chip complexity increases costs of field failures. At a 6-month high with 89% 1-month gain, the momentum is real but the stock is extended. Levels: Exit at Fib 1.272 of $172.34. Support at Fib 23.6% of $114.89. Caution: Up 90% in a month — this is a stock that rewards patience for pullbacks, not chasing at current levels.

Headlines to Watch

  • “Workday takeover chatter could mark a turning point for software stocks” — If Silver Lake confirms, this re-rates the entire enterprise SaaS sector; watch CRM, NOW, and DDOG for sympathy moves as PE firms signal software valuations have bottomed.
  • “Reddit added to S&P 500, effective August 18” — Forced index buying of ~3x average daily volume over the next 2 sessions creates a tradeable mechanical event; the inclusion effect is real but historically fades 5-10 days post-addition.
  • “Trump imposes 100% tariffs on drone imports” — Policy catalyst for domestic drone manufacturers (UMAC, RCAT, AVAV, KTOS) is genuine, but 48-hour fade risk is high — these moves are often “sell the news” by Monday.
  • “SanDisk $14B buyback + Korean KOSPI bull market” — Memory sector re-rating has multi-week legs if enterprise storage spending data from Morgan Stanley checks holds; this lifts MU and AMAT secondarily.
  • “Applied Materials falls 4% after earnings” — AMAT beat estimates but got sold — a warning that semiconductor equipment names priced for perfection face asymmetric downside risk; monitors KLAC and LRCX for contagion.
  • “Nu Holdings crosses $1B quarterly profit for first time” — Institutional re-rating of LatAm digital banking is underway; this is a secular story, not a trade, and may attract ESG/EM fund flows.
  • “Cooling PPI + retail sales data mixed” — Pantheon suggesting Fed stays on hold; stable rates support growth/tech multiples and reduce pressure on high-P/E names like RDDT and AEHR.

Claude’s Top Picks

RDDT (+11.2% today, +8.8% week) — $175.89 → $225.42 (+28.2% upside) Valuation: No comps provided, but 8 consecutive quarters of 60%+ revenue growth and S&P 500 index inclusion justify a significant premium to peers. Upside: S&P 500 inclusion on August 18 forces mechanical buying of ~3x daily volume; fundamental growth trajectory is one of the strongest in large-cap tech. Risk: Post-inclusion fade is historically sharp (average -5% to -8% in first 10 days after forced buying completes); this is a trade, not a buy-and-hold.

WIX (+16.5% today, +31.5% week) — $80.06 → $93.89 (+17.3% upside to 6mo high) Valuation: Flagrantly CHEAP — forward P/E of 11.2x vs. peer median of 44.6x; this is a 75% discount to peers while growing revenue at 14.9% with improving margins. Upside: AI platform launch (Symphony by Wix) + profitability inflection + valuation re-rating = three independent drivers; the 6-month high of $93.89 is the next clean technical target. Risk: RSI at 38.65 and already up 31.5% on the week — if the AI platform fails to show traction in Q3 metrics, the valuation re-rating thesis stalls.

NU (+13.4% today, +14.2% week) — $15.80 → $19.14 (+21.1% upside) Valuation: No comps in the data, but $1B+ quarterly profit and 49% YoY growth at a $75B market cap is reasonable for a digital banking leader in a 600M+ person LatAm market. Upside: Milestone profit quarter attracts new institutional and EM fund allocations; still 10% below 6-month high of $17.53, meaning this isn’t even a new-high chase. Risk: Brazilian real volatility or LatAm macro deterioration (inflation, rates) can compress NU’s credit book; currency risk is real and often underpriced.

HTFL (+23.3% today, +32.7% week) — $38.24 → $44.96 (+17.6% upside) Valuation: No comps provided, but 83.3% gross margin and 48% revenue growth is best-in-class for medtech SaaS; the sector typically trades at 8-12x revenue for this growth profile. Upside: Plaque Analysis is in early innings of CCTA market penetration; raised guidance + gross margin expansion = the kind of fundamental quality that sustains post-earnings moves. Risk: RSI at 34.5 entering today’s move sounds good, but up 32.7% in a week means some profit-taking is overdue; a pullback to $35 (Fib 23.6%) would be healthy and buyable.

SNDK (+13.7% today, +21.4% week) — $1,528.11 → $1,908.39 (+24.9% upside) Valuation: Trading at roughly 65% of its 6-month high of $2,335 — deeply discounted relative to its own history, with a sector re-rating catalyst in place. Upside: $14B buyback + enterprise storage strength confirmed by Morgan Stanley channel checks + Korean market re-rating = a multi-week recovery trade with real institutional support (80% WSB bullish, 1,521 upvotes with real follow-through). Risk: Memory is notoriously cyclical; if PC demand deterioration (flagged in the Morgan Stanley note) bleeds into enterprise storage, the recovery thesis cracks fast.

Avoid

AEHR — Up 90% in one month and 16% today alone; already at 6-month highs with the Fib 1.272 extension at $172.34 as the next target — you’re buying into a stock that’s had its entire year of gains compressed into four weeks. Wait for a pullback to the Fib 23.6% level of $114.89 before initiating.

UMAC — RSI at 70.8 (overbought) and the catalyst is a Trump tariff announcement — historically, drone tariff pumps fade within 48 hours as policy uncertainty returns. The 687% revenue growth is real, but a 20% single-day gain on top of an already-extended chart is a dangerous entry; let it breathe to $28-$30.

BRUN — RSI of 6.45 is one of the most extreme oversold readings in this dataset, yet it’s somehow up 13% today on a GPU lease announcement. An RSI that low while the stock has declined from $39.20 to $25.50 suggests serious underlying selling pressure that one lease deal won’t reverse. The 6-month chart shows this is a structural downtrend bouncing — classic “falling knife with a press release.”

WSB Sentiment Check

HTZ — WSB says: MIXED (55% bullish), 612 mentions, 1,397 upvotes Claude says: DISAGREE — HTZ is down 69% from its 6-month high of $7.81 to $2.41, trading below every Fib level, with SMA-50 at $2.83 acting as resistance overhead; this is a bankruptcy-risk trade dressed up as a value play, and the 55% bullish reading just means WSB is split on a coin flip — avoid.

SNDK — WSB says: BULLISH (80% bullish), 346 mentions, 1,521 upvotes Claude says: AGREE — For once, WSB’s thesis is backed by real fundamentals: $14B buyback, enterprise storage strength, Korean market re-rating, and the stock still 35% below its 6-month high; this is one of the cleaner risk/reward setups in the market today.

RDDT — WSB says: BULLISH (80% bullish), 274 mentions, 2,497 upvotes Claude says: AGREE (with caveats) — The S&P 500 inclusion is a mechanical forced-buy event that is real and tradeable through August 18, but history shows post-inclusion selling begins within a week; ride it to $184-185 resistance, then reassess.

MU — WSB says: MIXED (55% bullish), 258 mentions, 1,007 upvotes Claude says: PARTIALLY — MU at $956 is below both its 6-month high of $1,213 and its SMA-50 of $960, meaning it’s grinding along support in sympathy with SNDK’s rally; the memory re-rating thesis is valid, but MU needs to clear $990 (20d high) convincingly before it’s a buy, not just a hope.

AMAT — WSB says: BULLISH (80% bullish), 155 mentions, 343 upvotes Claude says: DISAGREE — AMAT just fell 4% post-earnings on a beat, which is the textbook definition of “priced for perfection + sell the news.” It’s trading at $512 against an SMA-50 of $559 and well below Fib retracements — WSB is buying a falling knife here. Wait for stabilization near $475 (Fib 61.8% support) before touching it.

Earnings Scorecard

NBIS (Nebius Group) — REPORTED | Stock: +6.1% | EPS: -$0.26 Reaction justified — AI data center neoclouds are in the monetization phase per Dan Ives, and NBIS is getting a re-rating alongside CRWV; a Bloom Energy partnership adding power demand visibility is a genuine fundamental catalyst, not just momentum. Not a dip-buy at these levels but the trend is intact.

BETA (Beta Technologies) — REPORTED | Stock: -4.7% | EPS: -$14.38 Reaction justified — 146% revenue growth sounds great until you see a -$14.38 EPS loss; pre-revenue eVTOL/electric aviation companies burning this much cash deserve skepticism, and $31.38 analyst target suggests the Street sees it as a “wait and see” situation. Avoid until cash burn trajectory improves.

AMAT (Applied Materials) — REPORTED | Stock: -4.0% | EPS: $11.60 Reaction was appropriate and possibly insufficient — AMAT beat on earnings but guidance disappointed relative to elevated expectations; at $512 vs. a $633 analyst target the gap sounds appealing, but semiconductor equipment is mid-cycle and China export restrictions remain an overhang. Wait for $475 Fib 61.8% support.

FLY (Firefly Aerospace) — REPORTED | Stock: +3.9% | EPS: -$4.94 Reaction understated — record revenue and backlog in a space launch company with genuine NASA/DoD contracts at a $45.80 analyst target vs. current price is a compelling setup; the market is giving this one away. Worth watching for a larger move once the broader space sector gets rotation attention.

INFQ (Infleqtion) — REPORTED | Stock: +3.6% | EPS: -$0.14 Reaction modest but fair — NASA-driven quantum computing revenue is real but early-stage; $20.60 analyst target vs. current price suggests upside, but the $100M raise and quantum computing commercialization timeline is measured in years, not quarters. Speculative hold only.

POET (POET Technologies) — REPORTED | Stock: +3.5% | EPS: -$0.84 Reaction appropriate — sixth straight quarter of revenue growth and on-schedule 2026 production ramp is encouraging for a photonics platform, but the EPS loss is still deep; the Lumentum photonics rally is providing sector tailwind. Sympathy bounce + modest fundamental progress = hold, don’t add.

COHR (Coherent Corp.) — REPORTED | Stock: -2.6% | EPS: $3.80 Reaction overdone — AI optics forecast actually beat estimates and the stock reversed higher intraday; the initial -2.6% on what was a beat suggests the market was looking for guidance uplift that didn’t fully materialize. With a $394 analyst target, this is more of a buy-the-dip scenario than a sell.

JD (JD.com) — REPORTED | Stock: -2.4% | EPS: $1.49 Reaction justified and potentially insufficient — first revenue decline since JD’s listing is a watershed negative moment; returning to operating profit while shrinking the top line means the growth story is broken. The -2.4% reaction seems light given the structural narrative shift; Chinese internet is facing a secular headwind, and JD specifically is losing share to PDD/Temu.

AIT (Applied Industrial) — REPORTED | Stock: +2.1% | EPS: $10.94 Reaction understated — record sales and earnings in industrial distribution with a $359.50 analyst target is a quality compounding story; the muted reaction reflects the boring-but-excellent nature of AIT. Not exciting, but a reliable swing trade on pullbacks.

LITE (Lumentum) — REPORTED | Stock: +2.0% | EPS: -$92.97 Reaction understated — the EPS figure is distorted by write-downs; the actual photonics/AI optics business drove an upbeat report that sparked the broader photonics rally (POET, COHR sympathy). Lumentum is a genuine AI infrastructure picks-and-shovels play. Buy-the-dip if it pulls back.

CAH (Cardinal Health) — REPORTED | Stock: -0.6% | EPS: $7.24 Reaction fair — Cardinal hit a record high post-earnings, then gave back slightly; at a $252 analyst target this is a steady-eddy healthcare distribution name with limited upside surprise potential. Hold if you own it, no reason to chase.

SMCI (Super Micro Computer) — REPORTED | Stock: +0.4% | EPS: $1.90 Reaction insufficient — SMCI’s AI server demand story is intact, and the market loved it more than Cisco per headlines, yet only +0.4% suggests the recent strong run has already priced in the beat. The $37.81 analyst target (apparently a holdover figure — seems inconsistent with current price) warrants verification. Hold existing positions; don’t add on this muted reaction.

This brief is for informational purposes. All technical levels and targets are derived from Fibonacci analysis of 6-month price ranges and should not be considered financial advice. Past performance does not guarantee future results.